NCT04910100View on ClinicalTrials.gov

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

April 29, 2022

Conditions
Open-Angle GlaucomaOcular Hypertension
Interventions
DRUG

Nebivolol Ophthalmic Suspension 1 Percent

1 drop instilled into each eye twice daily

DRUG

Nebivolol Ophthalmic Suspension 0.5 Percent

1 drop instilled into each eye twice daily

DRUG

Timolol Ophthalmic Suspension 0.5 Percent

1 drop instilled into each eye twice daily

DRUG

Timolol Ophthalmic Solution 0.5 Percent

1 drop instilled into each eye twice daily

Trial Locations (1)

92663

Site 0012, Newport Beach

Sponsors

Lead Sponsor

Betaliq, Inc.
All Listed Sponsors
collaborator

Trial Runners, LLC

OTHER

collaborator

Summit Analytical LLC

INDUSTRY

lead

Betaliq, Inc.

INDUSTRY

NCT04910100 - Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension | Biotech Hunter | Biotech Hunter